Skip to main content

Table 1 Overview of patients characteristics

From: Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy

Number of patients 48
Gender
 Male 32
 Female 16
 Unknown Gender 0
Histological subtype
 Adenocarcinoma 23
 Squamous-cell carcinoma 25
Age
 Mean | Median age at diagnosis (years) 64.65 | 64
 Range (years) 44–83
OS
 Deceased 34
 Alive 14
 Range (months) 2.13–78,7
 Median | Mean OS (months) 30.78 | 27.27
PFS
 Deceased 35
 Alive 13
 Range (months) 0.9–31.77
 Median | Mean PFS (months) 9.91 | 5.52
RECIST
 Partial response 18
 Stable disease 11
 Progressive disease 19
PD-L1 status
 TPS > 1% 29
 TPS < 1% 13
Treatment before immunotherapy
 Range (previous therapy lines) 2–7
 Chemotherapy (first-line) 48
 Radiation therapy in addition to chemotherapy 28
ECOG Performance Status
 ECOG = 0 1
 ECOG = 1 33
 ECOG = 2 12
 ECOG > 2 0
Immune-related adverse effects
 Patients affected by irAE 16
 Grade 1 irAE 6a
 Grade 2 irAE 8a
 Grade 3 irAE 7a
  1. aPatients can be affected by multiple ailments